Cardiovascular

dvancing heart health through innovative research

Heart Health Innovation

Our cardiovascular program focuses on developing treatments for heart disease, hypertension, arrhythmias, and vascular disorders. We conduct comprehensive trials with rigorous cardiac safety monitoring.

Our Capabilities

Heart failure trials
Acute coronary syndrome studies
Lipid management research
Cardiac imaging endpoints
Interventional cardiology trials
Cardiovascular safety assessments

Foundational Technologies & Key Targets

Molecular Targets

PCSK9: Proprotein convertase subtilisin/kexin type 9, a key regulator of cholesterol metabolism targeted for lifelong cholesterol management.

ANGPTL3: Angiopoietin-like protein 3, involved in lipid regulation for triglyceride reduction.

Apo(a): Apolipoprotein(a), component of lipoprotein(a) linked to cardiovascular risk.

Therapeutic Approaches

PCSK9 Inhibitors: Monoclonal antibodies that lower LDL cholesterol by preventing PCSK9 from degrading LDL receptors. Anticoagulants: Preventing blood clot formation in atrial fibrillation and thrombosis. Statins: HMG-CoA reductase inhibitors for cholesterol management.

Gene Therapy Applications

AAV-SERCA2a: Using AAV vectors to deliver SERCA2a gene for heart failure treatment, improving cardiac contractility. PCSK9 Gene Silencing: One-time AAV therapy to permanently reduce PCSK9 expression, providing sustained cholesterol reduction without continuous medication.

Advanced Monitoring

We utilize state-of-the-art cardiac monitoring including ECG, echocardiography, cardiac MRI, and biomarker analysis to ensure comprehensive assessment of cardiovascular effects and outcomes.

Integrated Research Excellence

Cardiovascular research demands meticulous coordination across multiple disciplines. Our Clinical Trials Management team coordinates complex cardiovascular outcomes trials with rigorous cardiac safety monitoring. Quality Assurance ensures impeccable ECG and imaging data quality, while Data Management handles sophisticated cardiac endpoints and event adjudication processes. Biostatistics specialists design trials with appropriate cardiovascular risk assessment methodologies. Regulatory Affairs navigates cardiac safety requirements across global markets, and Medical Writing delivers comprehensive cardiovascular safety narratives that meet regulatory expectations.